- ASH Agenda for Hematology Research
Read the ASH Agenda for Hematology Research, a roadmap for the prioritization of research support across the hematology community, including recommendations for dedicated resources from funding agencies and foundations that will equip researchers today and in the future to make truly practice-changing discoveries.
- Immunologic Treatments of Hematologic Malignancies: Moving Beyond Salvage Therapy to Curative Eradication of Minimal Residual Disease
Next-generation clinical studies will address important questions about emerging immunologic therapies but require an improved understanding of the basic biology of the immune system, including adaptive immunity, innate immunity, adjuvants, and tumor immune-surveillance.
- Genomic Profiling and Chemical Biology: Opportunities for Novel Targeted Therapies in Hematologic Disorders
As genomic profiling is driving significant research progress across the field, it is essential to adopt this technology in drug discovery efforts and build the infrastructure to integrate genomic medicine into the clinic.
- ASH Submits Recommendations to the NCI on the Cancer Moonshot Initiative
In response to a request for information from the National Cancer Institute (NCI) to advance progress against cancer through the Cancer Moonshot Initiative. ASH submitted recommendations to address research and clinical gaps that could accelerate the treatment of hematologic malignancies in precision, prevention, and early detection, expanding clinical trials, cancer immunology and prevention, enhanced data sharing, pediatric cancers, and tumor evolution and progression. ASH’s recommendations were based on the ASH Agenda for Hematology Research and ASH’s Recommendations to the Moonshot Initiative and were submitted through the NCI cancer research ideas platform. Members are encouraged to visit the NCI platform to read and/or comment on ideas submitted by ASH – the database can be filtered using keywords (e.g., ASH, hematology, blood disorders).